ODI Pharma (ODI) Q4 23/24 earnings summary

Executive summary

• Fiscal year marked by strategic partnerships, market expansion, and first Swiss market entry; focus shifted to core medical cannabis business after divesting skincare brand.

• Exclusive supply agreement with Synoptis Pharma expanded reach to 23 Eastern and Southeastern European countries.

• Revenue growth driven by increased orders in Poland and new partnerships; robust Q4 performance with SEK 7.5 million in sales.

Financial highlights

• Q4 net sales: SEK 7,544,320 (vs. SEK 38,418 same quarter last year); full-year net sales: SEK 22,447,125 (vs. SEK 139,457 prior year).

• Q4 profit after financial items: SEK -1,111,243 (vs. SEK -1,896,506); full-year profit after financial items: SEK 544,560 (vs. SEK -6,895,119).

• Q4 EPS: SEK -0.08 (vs. SEK -0.12); full-year EPS: SEK 0.02 (vs. SEK -0.45).

• Group total assets at year-end: SEK 12,274,994 (vs. SEK 8,185,554); equity: SEK 2,217,320 (vs. SEK 2,572,681).

• Cash flow from operations Q4: SEK -179,413 (vs. SEK -1,822,773); cash and cash equivalents at year-end: SEK 2,637,906 (vs. SEK 6,492,804).

Outlook and guidance

• Focus remains on expanding presence in existing and new European markets, leveraging regulatory changes and rising demand for medical cannabis.

• Strategic partnerships and market expertise to drive long-term, sustainable growth.